Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by SanFrancisco99on Mar 09, 2015 8:17pm

309 Views

Post# 23504403

RE:Resverlogix Q&A From Today

I think there is a very important point in the answer to question #1 - something I was personally not clear on until now.

Make no mistake: We are talking about (potentially) THREE Phase 3 trials. Not one trial with various parts. But three separate Phase 3 trials.

And funding is apparently not a concern on their part either.

That's pretty amazing IMHO. Wow.

DYODD. GLTA.

Bullboard Posts

Southern Ontario mineral processing operation receives green fund support